Pathological involvement of the noradrenergic locus coeruleus occurs early in Parkinson's disease, and widespread noradrenaline reductions are found at post-mortem. Rapid eye movement sleep behaviour disorder (RBD) accompanies Parkinson's disease and its presence predicts an unfavourable disease course with a higher propensity to cognitive impairment and orthostatic hypotension. MRI can detect neuromelanin in the locus coeruleus while 11 C-MeNER PET is a marker of noradrenaline transporter availability.
Introduction
Noradrenergic innervation of the brain arises almost exclusively from the neuromelanin-containing cells of the locus coeruleus. Depositions of aggregated a-synuclein in the locus coeruleus occur early in Braak stage 2 of Parkinson's disease (Braak et al., 2001) . Post-mortem studies have detected a substantial noradrenergic deficit in Parkinson's disease patients (Kish et al., 1984) . However, in vivo assessment of the noradrenergic system has been hampered by the lack of suitable imaging tools. Recently, neuromelanin-sensitive MRI sequences have been introduced, capable of delineating the pigment in the cell bodies in the locus coeruleus (Keren et al., 2015) . Additionally, 11 C-MeNER, a PET reboxetine analogue with a high specificity for noradrenaline transporters has been developed (Schou et al., 2003) . These imaging modalities have been successfully used to study locus coeruleus changes and noradrenergic transporter function in Parkinson's disease (Garcia-Lorenzo et al., 2013; Nahimi et al., 2017) .
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a sleep disorder defined by deficient muscle atonia and dream enactment during REM sleep. Parkinson's disease patients with RBD (PD RBD + ) are at high risk of developing cognitive impairment (Jozwiak et al., 2017) . Additionally, this subpopulation also displays a high prevalence of autonomic disturbances (Postuma et al., 2008) . Interestingly, these non-motor symptoms often coincide suggesting a common neurobiological factor (Udow et al., 2016) . The noradrenergic system mediates cognitive attention, regulates the sleep cycle and influences cardiac function via widespread projections from the locus coeruleus to the cortex, brainstem nuclei and the hypothalamus (Rodovalho et al., 2006; Vazey and AstonJones, 2012) ; thus, noradrenergic degeneration might be the candidate. The pathophysiology of RBD is not fully understood, but rodent models indicate a substantial role of the sublaterodorsal nucleus in establishing REM atonia, which corresponds to the locus subcoeruleus in humans (Valencia Garcia et al., 2017) . These cells contain neuromelanin in humans and are located dorsoventrally to the locus coeruleus; both parts are often assimilated into the subcoeruleus/coeruleus complex (Braak et al., 2001; Garcia-Lorenzo et al., 2013) . Recent neuromelanin sensitive magnetic resonance sequences have revealed a loss of neuromelanin signal from this complex in PD RBD + (GarciaLorenzo et al., 2013) . We hypothesize that damage to the subcoeruleus/coeruleus complex might represent a common pathway for RBD genesis, cognitive decline, and orthostatic dysregulation.
The objective of this combined 11 C-MeNER PET and neuromelanin-sensitive MRI study was to examine the hypothesis that the noradrenergic system is more severely affected in PD RBD + compared to Parkinson's disease patients without RBD (PD   RBDÀ   ) . Additionally, we aimed to investigate the relationship between levels of noradrenergic function, cognition and autonomic regulation in Parkinson's disease. , age 50-85 years, a Geriatric Depression Scale (GDS-15) score 56 and MoCA 422. Exclusion criteria were: a diagnosis of dementia, medication interacting with the noradrenaline transporter, and significant white matter lesions. Patients were recruited through advertisement in the Danish Parkinson's disease magazine and from collaborating neurological clinics. Total levodopa-equivalent daily doses were calculated as previously recommended (Tomlinson et al., 2010) . Motor symptoms were quantified using the MDS Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS III) after 12 h of medication abstinence. Olfaction was tested with the 16-item Sniffin' Sticks, RBD symptoms were assessed using the RBD symptom questionnaire (RBDSQ). Parkinson's disease patients were compared to 12 age-and sex-matched, cognitive normal (MoCA 426) and non-depressed (GDS-15 56) healthy control subjects without history of neurological disorders and with normal brain MRI (Table 1) . Six additional healthy control subjects-part of an in-house neuromelanin MRI control sample-fulfilling the aforementioned criteria were included for neuromelanin MRI analysis. All healthy control subjects were recruited through newspaper advertisements.
Material and methods

Study design and participants
The study was approved by the local ethical committee; all subjects gave informed written consent according to the Declaration of Helsinki.
MRI
Subjects were scanned with a 3 T SIEMENS MAGNETOM TRIO scanner; the protocol included T 1 and fluid-attenuated inversion recovery (FLAIR) images. Neuromelanin sensitive images were acquired with 2D axial turbo spin echo T 1 -weighted sequences (repetition time/echo time: 600 ms/ 9.9 ms, 16 averages, voxel size: 0.4 Â 0.4 Â 1.8 mm). Planes were acquired perpendicular to the dorsal brainstem, and a locus coeruleus-to-pons ratio was calculated using PMOD 3.8: a template volume of interest for each side of the locus coeruleus, derived from previously published MNI atlas coordinates (Keren et al., 2009) , was transformed to the individual MRI, and adjusted manually for precise localization if needed. The 10 voxels with highest intensity were extracted from each volume of interest and divided by the background level derived from a rectangular volume of interest centred in the pons, and both values were averaged. Blinded inter-rater assessment (M.S. and T.F.) revealed high agreement (R 2 = 0.913), and the average of both raters of MRI neuromelanin locus coeruleus-to-pons ratios was taken for group comparisons. To assess the association of MRI and 11 C-MeNER PET signals, we interrogated correlations between locus coeruleus-to-pons ratios and 11 C-MeNER distribution volume ratios (DVRs).
C-MeNER PET
11
C-MeNER radiosynthesis was performed as described previously (Nahimi et al., 2017) . After a transmission scan and at the start of a bolus administration of 11 C-MeNER, a 90-min dynamic PET scan was acquired with an ECAT HRRT in list mode. We analysed PET images with relevant toolboxes of PMOD 3.8, including time frame realignment for motion correction. All PET images were then normalized into Montreal Neurological Institute (MNI) space including rigid matching of subject's PET to the anatomical MRI, and MRI segmentation. We defined six noradrenaline transporter rich regions (thalamus, hypothalamus, red nucleus, locus coeruleus, median raphe, dorsal raphe) for volume of interest analysis and used the occipital cortex as a reference region; thalamus and occipital cortex were defined from the built-in Hammers N30R83 atlas. Volumes of interest of the locus coeruleus and dorsal and median raphe were drawn accordingly to published details (Keren et al., 2009; Kranz et al., 2012) . Red nucleus volumes of interest were defined on individual FLAIR images and transformed to MNI space; hypothalamus volumes of interest were defined by their surrounding structures. To optimize kinetic modelling, we smoothed PET images with a 4 mm Gaussian filter and extracted time activity curves from volumes of interest for calculation of distribution volume ratios (DVRs) with the simplified reference tissue model 2 (SRTM2) for group comparisons. For illustration purposes (Fig. 1) , parametric maps of SRTM2 DVRs were generated. More details of PET analysis are given in the Supplementary material.
Polysomnography and EEG
We used a SOMNOscreen TM plus Tele + Video device for overnight video-polysomnography including 10 EEG electrodes, right and left electrooculogram, nasal pressure monitoring, thoracic and abdominal effort belts, electrocardiogram, pulse oximetry, EMG of the submental and tibialis anterior muscles, and video monitoring. Presence of RBD was judged according to the current consensus criteria from the American Academy of Sleep Medicine. Quantitative EMG analysis of 'phasic' (representing brief activity 515 s), 'tonic' (representing sustained activity 415 s), and 'any' (representing any activity) submental muscle activity during REM sleep was performed with a validated computer algorithm, which was recently developed by our group and shown to have high congruency with human visual ratings (R 2 4 0.9). The semi-automated computer algorithm was based on previously proposed visual scoring criteria by McCarter et al. (2014) . As REM sleep atonia is supposed to be mediated by brainstem nuclei interplay (Boeve et al., 2007) , we correlated the 11 C-MeNER PET signal in the corresponding areas (locus coeruleus and raphe nuclei) with measures of quantitative EMG analysis.
EEG was performed under ambient conditions with the subject awake and resting with closed eyes. We extracted 30 s artefact-free epochs to calculate alpha (8-13 Hz) and theta (4-8 Hz) power, and background frequency (correspondent to the frequency with highest power in the spectrum) using the Natus Viewer software and the built-in band power report. Signals of the O1 and O2 electrodes were prefiltered with 3 Hz high-pass and 15 Hz low-pass filters, and results of both EEG electrodes were averaged and used for group comparisons. Slowing of EEG background frequency was reported to herald cognitive decline in Parkinson's disease patients (Klassen et al., 2011; Latreille et al., 2016) , and as locus coeruleus firing pattern was reported to have high congruency to the cortical EEG signal (Bari and Aston-Jones, 2013), we selected the 11 C-MeNER binding in the locus coeruleus for correlation analysis with EEG.
Neuropsychological assessment
Cognition was assessed adhering to the 2012 MDS diagnostic criteria for mild cognitive impairment in Parkinson's disease (Litvan et al., 2011) . Mild cognitive impairment was diagnosed when two cognitive tests revealed z-scores below À1.5 and there was a history of cognitive complaints reported by the subject or spouse on our questionnaire (Koster et al., 2015) . Tests included Rey auditory verbal learning test, and the location learning test for memory domain; digit span backwards, letter number sequencing task, and Stroop colour and word test for working memory; Wisconsin card sorting test, and phonemic verbal fluency (-s version) for executive functioning; similarities test, semantic verbal fluency (animals), and the 30-item Boston naming test for language abilities; Benton judgement of line orientation, clock drawing and visual puzzles for visuospatial function. Z-scores for each cognitive domain were calculated based on published age corrected norms, if available, and from an in-house Danish cohort of healthy subjects matched for age. A composite score of the average of the five domain z-scores was calculated to estimate global cognitive performance. This global score was used for correlation analysis with the 11 C-MeNER PET signal of the locus coeruleus. Premorbid cognitive function was estimated with the Wechsler Adult Intelligence Scale (WAIS)-IV vocabulary test and scale scores were comparable across groups (healthy control, 10.6 AE 2.4, PD RBDÀ , 10.4 AE 2.0, PD RBD + , 9.7 AE 1.7; P = 0.669).
Autonomic assessment
Symptoms of autonomic disturbances were assessed with rating scales for outcomes in Parkinson's disease -autonomic (SCOPA-AUT); due to incomplete response rates on items 22-25 (questions about sexual ability), these sections were excluded. After 415 min rest in the supine position, blood pressure was measured for three consecutive C-MeNER DVR of the groups with corresponding anatomical MRI on the left; top row is a paramedian section through thalamus, red nucleus, and hypothalamus; bottom row is a median section through brainstem nuclei.
minutes after tilting. Orthostatic hypotension was defined as systolic pressure drop of 20 mmHg or diastolic pressure drop of 10 mmHg within the first 3 min of standing (The Consensus Committee of the American Autonomic Society and the American Academy of Neurology, 1996) . Blood pressure measurements were not undertaken at a fixed time of day, but were usually performed between 10 am and 2 pm. We calculated the mean changes of systolic pressure and diastolic pressure during the 3 min of upright position and subtracted the mean from the supine blood pressure for group comparisons. We selected the 11 C-MeNER PET signals of locus coeruleus and hypothalamus, which are noradrenergic centres of blood pressure regulation (Rodovalho et al., 2006) , for correlation with blood pressure changes. Blood pressure measurements were not undertaken in two PD RBD + subjects because of atrial fibrillation and beta-blocker therapy, and in two PD RBD + subjects and one healthy control subject because of technical failure of the blood pressure monitor.
Statistical analysis
We interrogated the data with the Statistical Package for the Social Sciences (SPSS) version 24. Group data are presented as mean AE standard deviation (SD) if not otherwise stated. Group comparisons were performed with one-way ANOVA, Student's t-tests, Mann-Whitney tests, KruskalWallis tests, and chi-square tests as appropriate; a normal distribution of data was assessed with Shapiro-Wilk tests, Q-Q plots, and box plots. Univariate correlation analyses were calculated with Pearson's r and Spearman's rho as appropriate. For volume of interest-based PET analysis, a linear mixed model for repeated measures with the random effect 'subject', the between-subjects factor 'group', and the within-subjects factor 'brain region' was calculated; the interaction term of 'brain region' Â 'group' was included in model calculation. Significance was accepted at P 5 0.05.
Results
Decreased noradrenergic imaging-markers in PD RBD + patients
In accordance with their RBD diagnosis, PD RBD + patients scored higher on the RBDSQ and had extensive epochs of REM sleep without atonia for all three muscle activity categories. The Parkinson's disease subgroups and healthy control subjects were otherwise comparable with regard to demographic and clinical characteristics (Table 1 ).
11
C-MeNER DVRs differed significantly between the groups and the PD RBD + patients exhibited the lowest mean values in all examined brain regions (group effect P 5 0.001; healthy control versus PD RBDÀ , P = 0.027; healthy control versus PD RBD + , P 5 0.001; PD RBDÀ versus PD RBD + , P = 0.001). The interaction term of 'brain region' Â 'group' was highly significant (P = 0.004), and the decrease of regional 11 C-MeNER DVRs was most pronounced in brainstem nuclei in PD RBD + patients (Fig. 1) . PD RBD + patients also displayed the lowest neuromelanin locus coeruleus-topons ratio on MRI (group effect P 5 0.001; healthy control versus PD RBDÀ , P = 0.014; healthy control versus PD RBD + , P 5 0.001; PD RBDÀ versus PD RBD + , P = 0.026; Fig. 2A and B). Locus coeruleus-to-pons ratios from neuromelanin MRI correlated with thalamic 11 C-MeNER DVR levels in pooled analysis but did not correlate with other regional 11 C-MeNER DVR levels (rho = 0.339, P = 0.030 for thalamus; Fig. 2C ). Representative coronal sections of the dorsal brainstem on neuromelanin sensitive MRI of a healthy control subject with locus coeruleus-to-pons ratio of 1.36 (top) and of a PD RBD + subject with locus coeruleus-to-pons ratio of 1.25 (bottom); images were normalized to the intensity of the pons. The locus coeruleus is typically visible as a bilateral, hyperintense, longitudinal structure in the dorsal pons in healthy subjects as seen in the top image, but disappears in PD RBD + subjects (bottom). (C) Correlation of individual neuromelanin MRI locus coeruleus-to-pons ratios with 11 C-MeNER DVRs of the thalamus (rho = 0.339, P = 0.030 for all groups combined). HC = healthy control; LC = locus coeruleus.
The amount of muscle activity in REM sleep correlated negatively with 11 C-MeNER DVR of the locus coeruleus in PD RBD + patients (r = À0.623, P = 0.013 for 'any', r = À0.678, P = 0.006 for 'tonic', and r = À0.551, P = 0.033 for 'phasic' activity; Fig. 3) ; no correlations were significant between amount of EMG activity and raphe 11 C-MeNER DVR or MRI locus coeruleus-to-pons ratio.
Correlation of noradrenergic imaging-markers with cognition and autonomic regulation PD RBD + patients showed a lower performance in all cognitive domains, which reached significance in the visuospatial domain, and they had an increased prevalence of mild cognitive impairment (Table 2) . PD RBD + patients also showed significantly slower EEG background frequency compared to PD RBDÀ patients and healthy controls, and by extension, higher theta power and a lower alpha/theta power ratio (Table 2 ).
C-MeNER DVRs of the locus coeruleus correlated with global cognitive performance in Parkinson's disease patients as well as in pooled analysis with healthy control subjects (r = 0.399, P = 0.029, and r = 0.394, P = 0.010, respectively); similar correlations were obtained with EEG background frequency (r = 0.404, P = 0.033, and r = 0.490, P = 0.001 for pooled analysis, respectively) ( Fig. 4A and B) . MRI locus coeruleus-to-pons ratios did not correlate with background frequency or cognitive performance.
Subjective complaints of autonomic symptoms were more prevalent in Parkinson's disease patients compared to healthy control subjects and orthostatic hypotension was most prevalent in PD RBD + patients (50%, P = 0.026). Upon tilting, PD RBD + patients exhibited a blunted blood pressure response with a significant fall of systolic pressure (À12.2 AE 17.9 mmHg, P = 0.019) ( Table 2 ). Blood pressure falls correlated significantly with 11 C-MeNER DVRs of the locus coeruleus and hypothalamus in the pooled analysis (systolic pressure: r = 0.375, P = 0.022 and r = 0.286, P = 0.086; diastolic pressure: r = 0.339, P = 0.040 and r = 0.367, P = 0.025), but significance was not achieved in the analysis of Parkinson's disease patients alone ( Fig. 4C and D) . No correlation was observed between MRI locus coeruleus-to-pons ratios and blood pressure changes.
Discussion
In this study, we examined structure and function of the noradrenergic system in Parkinson's disease patients with multimodal imaging. We targeted the pigmented cell bodies of the locus coeruleus with neuromelanin sensitive MRI, and noradrenaline transporters in relevant brain regions with 11 C-MeNER PET. Both modalities showed marked reductions of signal in Parkinson's disease patients, most pronounced in PD RBD + patients, and decline of 11 C-MeNER binding was associated with magnitude of abnormal muscle activity during REM sleep. PD RBD + patients showed slowed EEG activity and a higher incidence of cognitive impairment and orthostatic hypotension. These conditions were associated with reduced 11 C-MeNER binding in regulatory noradrenergic brain areas.
Parkinson's disease patients exhibited the lowest 11 C-MeNER binding in all examined brain regions as well as the lowest neuromelanin signal on MRI; however, neuromelanin MRI and 11 C-MeNER PET signals were not well correlated. Several studies on Parkinson's disease patients and animal lesion models have reported a lack of correlation between dopaminergic neuronal density in the substantia nigra and the integrity of striatal dopaminergic terminals. When data from subjects with and without dopaminergic deficit were pooled, however, a correlation was observed (Karimi et al., 2013; Kraemmer et al., 2014) . A 'dying-back' concept of the dopaminergic system has been postulated in the context of Parkinson's disease, Each symbol represents one subject and 11 C-MeNER DVR of the locus coeruleus is plotted against the percentage amount of REM sleep with 'any' activity (A), 'tonic' activity (B), and 'phasic' activity (C). Correlations were calculated in the PD RBD + group only (r = À0.623, P = 0.013 for 'any', r = À0.678, P = 0.006 for 'tonic', and r = À0.551, P = 0.033 for 'phasic' activity). As control subjects elicited only marginal muscle activity during REM sleep, they were not included in data presentation.
i.e. axonal and terminal degeneration prior to neuronal cell loss, which may also apply to the noradrenergic system (Cheng et al., 2010) . Nevertheless, dying back does not explain an absent correlation between structural and functional imaging modalities in the locus coeruleus itself. Monoaminergic transporters and receptors undergo adaptive changes in Parkinson's disease and so their availability may not show a proportional relationship with the magnitude of neuronal death of corresponding cell bodies. Additionally, while the noradrenergic locus coeruleus signalling is largely integrative, neurons display significant heterogeneity in their regional projections (Kebschull et al., 2016) . Thus, it is perhaps not unexpected that the neuromelanin MRI signal as a marker of the integrity of locus coeruleus cell bodies did not correlate with regional noradrenalin transporter density measured with 11 C-MeNER PET in brain structures exhibiting differential noradrenergic inputs. However, since PD RBD + patients showed decreased signal on both imaging modalities, it suggests that noradrenergic damage is profound and widespread in this Parkinson's disease subpopulation.
In addition to the difference of PD RBD + patients as a group, we also detected a negative correlation of 11 C-MeNER binding in the locus coeruleus with the amount of muscle activity in REM sleep, strengthening the association of noradrenergic alterations to key symptoms of RBD. Of note, noradrenergic enhancing drugs increase the amount of muscle activity during REM sleep, and the locus coeruleus is known to cease firing during REM sleep as part of a sleep-stage switch (Lu et al., 2006) . This evidence points to a substantial role of noradrenergic signalling in normal REM sleep regulation and as a mediator of REM sleep atonia. However, converging evidence from animal research suggests that activation of the glutamatergic sublaterodorsal nucleus establishes REM atonia (Valencia Garcia et al., 2017) . Nevertheless, it remains unsolved, whether the homologous locus subcoeruleus in humans is also glutamatergic, especially since it contains neuromelanin pigment, which is typically expressed in catecholaminergic neurons. Additionally, cells in the locus subcoeruleus express a2-adrenergic receptors, which when activated inhibit the output from these cells that is necessary to establish REM atonia (Yang et al., 2014) . Thus, deficient noradrenergic signalling might interact at the level of the sleep stage switch, resulting in inefficient REM sleep stage transition with 'leaking' of muscle activity during REM sleep. Alternatively, non-physiological activation of the nucleus subcoeruleus during REM sleep may result from insufficient inhibition from the locus coeruleus. Our findings may also simply represent a mutual affection of the locus subcoeruleus/ coeruleus complex in Parkinson's disease, as these structures are well interconnected and situated closely together (Braak et al., 2001) . It would have been interesting to explore correlation of RBD symptom duration with noradrenergic imaging parameters in our Parkinson's disease cases but many cases were unable to accurately date the onset of their sleep disorder.
A heterogeneous clinical presentation and prognosis of Parkinson's disease patients is increasingly recognized, and in a recent longitudinal study, the presence of RBD, mild cognitive impairment, and orthostatic hypotension were the best predictors of a diffuse/malignant phenotype of Parkinson's disease (Fereshtehnejad et al., 2015) . In our study, PD RBD + patients also showed higher propensity to cognitive impairment and orthostatic hypotension in agreement with previous studies (Postuma et al., 2008; Udow et al., 2016; Jozwiak et al., 2017) . Hence, a common neurobiological premise for RBD, cognitive deterioration, and orthostatic disturbances in Parkinson's disease seems plausible and indeed, we detected associations between the noradrenergic system as measured with 11 C-MeNER PET and all three conditions. 11 C-MeNER not only correlated with global cognitive performance but also with EEG activity, which was slowed in PD RBD + patients. Slowing of EEG is commonly seen in several forms of dementia, and was previously shown to be highly predictive for the development of dementia in Parkinson's disease (Klassen et al., 2011) . However, maintaining healthy cognition is dependent on several neurotransmitter systems and particularly the loss of cholinergic signalling is a well-known cause of cognitive decline in Parkinson's disease (Bohnen et al., 2015) . Nevertheless, locus coeruleus terminals exhibit a brain-wide distribution and are known to modulate various neurotransmitters via adaption of their firing pattern and divergent postsynaptic effects due to different noradrenergic receptors (Schwarz and Luo, 2015) . This may be particularly important in early to mid-stage Parkinson's disease when a-synuclein pathology has not yet spread to the majority of cortical regions, but is mostly confined to brainstem areas (Braak et al., 2001) . Accordingly, and given the results of the present study, the noradrenergic system should be a considered therapeutic target in Parkinson's disease. Some studies have already pointed to beneficial effects of noradrenergic enhancement by atomoxetine and droxidopa on cognition and blood pressure control (Weintraub et al., 2010; Kaufmann et al., 2014) , and studies with these compounds are currently on-going.
Several limitations of our study should be noted. First, the sample size of 42 subjects is modest, but still represents a high standard for PET studies. Some volumes of interest used in the study are not clearly defined on anatomical MRI and we had to use previously recommended definitions in MNI space coordinates (Keren et al., 2009; Kranz et al., 2012) . Blood pressure regulating medication was not withdrawn prior to orthostatic testing; however, prevalence of treatment did not differ between groups. We also did not control for circadian variation of blood pressure regulation as measurements were not performed at a fixed daytime. These factors might have contributed to reduced statistical power of our blood pressure analysis.
In conclusion, we found that noradrenergic impairment in Parkinson's disease is linked to the presence of RBD and correlated with its key characteristic of increased muscle activity during REM sleep. Noradrenergic impairment might also contribute to the high prevalence of cognitive decline and orthostatic hypotension in Parkinson's disease patients, especially in patients with RBD, and might point to new options for treatment of these conditions.
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